Original Literature | Model OverView |
---|---|
Publication
Title
Toll like receptors and autoimmunity: a critical appraisal.
Affiliation
Department of Internal Medicine and Division of Rheumatology, Immunology andAllergy, University of Crete, Medical School, Voutes 71500, Heraklion, Greece.
Abstract
There is a constant interplay between the innate and adaptive immune systems,which leads to a protective immune response against pathogens and contributeseffectively to self-non-self discrimination. Toll-like receptors (TLRs) are keycomponents of the innate immune system, which activate multiple inflammatorypathways and coordinate systemic defense against pathogens. In addition torecognizing unique molecular patterns associated with different classes ofpathogens, TLRs may also recognize a number of self proteins and endogenousnucleic acids. Data originating predominantly from animal models of autoimmunedisease and circumstantial data from human patients suggest that inappropriateactivation of TLR pathways by endogenous or exogenous ligands may lead to theinitiation and/or perpetuation of autoimmune responses and tissue injury.
PMID
17959357
|
Entity
Process
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17
10
infinite
0
TRANSPATH | MO000000058 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IRAK-1
--
MO000000213
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m184
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000000213 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
ROS
--
MO000008272
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1063
10
infinite
0
TRANSPATH | MO000008272 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
IFNalpha1
--
MO000016659
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1635
10
infinite
0
InterPro | IPR000471 |
TRANSPATH | MO000016659 |
--
MKK7 {activated}
--
MO000016916
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1831
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016916 |
--
fibrinogen
--
MO000017426
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m2254
10
infinite
0
TRANSPATH | MO000017426 |
--
fibronectin
--
MO000017549
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m2341
10
infinite
0
InterPro | IPR006209 |
TRANSPATH | MO000017549 |
--
modofied low density lipoprotein
--
MO000017793
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2549
10
infinite
0
TRANSPATH | MO000017793 |
--
TBK1
--
MO000019331
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3902
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019331 |
--
TLR4
--
MO000019394
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3961
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019394 |
--
TLRs
--
MO000019395
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3962
10
infinite
0
TRANSPATH | MO000019395 |
--
TLR2
--
MO000019397
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3964
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019397 |
--
TLR3
--
MO000019398
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3965
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019398 |
--
protein remnants
--
MO000019479
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m360980
10
infinite
0
TRANSPATH | MO000019479 |
--
dsRNA:TLR3:TRIF
--
MO000041437
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19305
10
infinite
0
TRANSPATH | MO000041437 |
--
dsRNA:TLR3
--
MO000041446
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19314
10
infinite
0
TRANSPATH | MO000041446 |
--
TLR9
--
MO000042012
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19828
10
infinite
0
TRANSPATH | MO000042012 |
--
TLR7
--
MO000042126
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19940
10
infinite
0
TRANSPATH | MO000042126 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
hyaluronate: TLR4
--
e100
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m104
0
infinite
0
--
modofied low density lipoprotein: TLR4
--
e101
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m105
0
infinite
0
--
fibronectin: TLR
--
e102
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m106
0
infinite
0
--
peptidoglycan
--
e103
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m107
0
infinite
0
--
peptidoglycan: TLR2
--
e104
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m108
0
infinite
0
--
csml-variable:Double
m109
10
infinite
0
Affymetrix | 1369_s_at |
Ensembl | ENSG00000169429 |
HGNC | IL8 |
OMIM | 146930 |
Proteome | HumanPSD/IL8 |
RefSeq | NM_000584 |
TRANSFAC | G000317 |
Unigene | Hs.551925 |
--
MMP
--
e106
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m110
0
infinite
0
--
urate crystals
--
e107
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m111
0
infinite
0
--
urate crystals: TLR4
--
e108
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m112
0
infinite
0
--
urate crystals: TLR2
--
e109
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m113
0
infinite
0
--
--
e11
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m11
0
infinite
0
--
IFN type I
--
e110
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m114
0
infinite
0
--
poly I:C
--
e111
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m115
0
infinite
0
--
poly I: C: TLR3
--
e112
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m116
0
infinite
0
--
imiquimod
--
e113
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m117
0
infinite
0
--
imiquimod: TLR7
--
e114
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m118
0
infinite
0
--
CXCL-10
--
e115
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m119
0
infinite
0
--
CXCL-10
--
e116
cso30:c:Protein
cso30:i:CC_Extracellular
--
csml-variable:Double
m120
0
infinite
0
--
LPS: TLR4
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m12
0
infinite
0
--
TLR2: TLR6
--
e13
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m13
0
infinite
0
--
TLR2: TLR1
--
e14
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m14
0
infinite
0
--
Lipotechoic acid
--
e15
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m15
0
infinite
0
--
Lipotechoic acid: TLR2: TLR6
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m16
0
infinite
0
--
Triacylated lipopeptide: TLR2: TLR1
--
e17
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m18
0
infinite
0
--
Triacylated lipopeptide
--
e18
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m19
0
infinite
0
--
flagellin: TLR5
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m20
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR ligand
--
e20
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m21
0
infinite
0
--
TLR ligand: TLR
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m22
0
infinite
0
--
CpG oligonucleotide
--
e22
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m23
0
infinite
0
--
CpG oligonucleotide: TLR9
--
e23
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m24
0
infinite
0
--
zymosan
--
e24
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m25
0
infinite
0
--
zymosan: TLR2: TLR6
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m26
0
infinite
0
--
F protein of RSV
--
e26
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m27
0
infinite
0
--
F protein of RSV: TLR4
--
e27
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m28
0
infinite
0
--
ssRNA
--
e28
cso30:c:Rna
cso30:i:CC_Extracellular
--
csml-variable:Double
m29
0
infinite
0
--
ssRNA: TLR7
--
e29
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m30
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
ssRNA: TLR8
--
e30
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m31
0
infinite
0
--
Hsp60: TLR4
--
e31
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m32
0
infinite
0
--
fibrinogen products
--
e32
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m33
0
infinite
0
--
fibrinogen products: TLR4
--
e33
cso30:c:Complex
cso30:i:CC_Extracellular
--
csml-variable:Double
m34
0
infinite
0
--
TLR{ub}
--
e34
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0
infinite
0
--
TLR
--
e35
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m36
0
infinite
0
--
TLR ligand: TLR: MyD88
--
e36
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m37
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-4: IRAK-1
--
e37
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m38
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-4: IRAK-1: TRAF6
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m41
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
NF-kappaB {activated}
--
e40
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m42
10
infinite
0
TRANSPATH | MO000000058 |
--
MKK3 [activated}
--
e41
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m43
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000016966 |
--
MKK6 {activated}
--
e42
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m44
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019005 |
--
AP-1 {activated}
--
e48
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m65
10
infinite
0
TRANSPATH | MO000000276 |
--
NF-kappaB {nucleus}
--
e49
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m66
10
infinite
0
TRANSPATH | MO000000058 |
--
--
e5
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
--
e6
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
inflammatory cytokines
--
e63
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m67
0
infinite
0
--
ssRNA: TLR7: MyD88
--
e64
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m68
0
infinite
0
--
ssRNA: TLR8: MyD88
--
e65
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m69
0
infinite
0
--
CpG oligonucleotide: TLR9: MyD88
--
e66
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m70
0
infinite
0
--
IRAK-1 {activated}
--
e67
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m71
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000000213 |
--
TRAF6 {activated}
--
e68
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m72
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
TBK1 {activated}
--
e69
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m73
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000019331 |
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
IRF-7 {activated}
--
e70
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m74
10
infinite
0
TRANSPATH | MO000007702 |
--
IRF-3 [activated}
--
e71
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m75
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
TARF6: TBK1
--
e72
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m76
0
infinite
0
--
IRF-3 [activated}
--
e73
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m77
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
protosoal GPI
--
e74
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m78
0
infinite
0
--
protosoal GPI: TLR2
--
e75
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m79
0
infinite
0
--
LPS: TLR4: TIRAP
--
e76
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m80
0
infinite
0
--
LPS: TLR4: TIRAP: MyD88
--
e77
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m81
0
infinite
0
--
zymosan: TLR2: TLR6: TIRAP
--
e78
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m82
0
infinite
0
--
zymosan: TLR2: TLR6: TIRAP: MyD88
--
e79
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m83
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
fibrinogen: TLR2
--
e80
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m84
0
infinite
0
--
hyaluronate
--
e81
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m85
0
infinite
0
--
hyaluronate: TLR2
--
e82
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m86
0
infinite
0
--
TGF-beta
--
e83
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m87
10
infinite
0
TRANSFAC | G010254 |
--
TBK1 {activated}: IKK-i
--
e84
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m88
0
infinite
0
--
adaptor mediating TRIF pathway
--
e85
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m89
0
infinite
0
--
LPS: TLR4: adaptor mediating TRIF pathway
--
e86
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m90
0
infinite
0
--
LPS: TLR4: adaptor mediating TRIF pathway: TRIF
--
e87
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m91
0
infinite
0
--
endogenous ssRNA
--
e88
cso30:c:Rna
cso30:i:CC_Extracellular
--
csml-variable:Double
m92
0
infinite
0
--
endogenous ssRNA: TLR7
--
e89
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
--
csml-variable:Double
m93
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
endogenous ssRNA: TLR8
--
e90
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m94
0
infinite
0
--
endogenous hypomethylated DNA
--
e91
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m95
0
infinite
0
--
endogenous hypomethylated DNA: TLR9
--
e92
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m96
0
infinite
0
--
pathogenic antibody
--
e93
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m97
0
infinite
0
--
hydroxychloroquine
--
e94
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m98
0
infinite
0
--
CpG ODN
--
e95
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m99
0
infinite
0
--
CpG ODN: TLR9
--
e96
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m100
0
infinite
0
--
endogenous ssRNA: TLR3
--
e97
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m101
0
infinite
0
--
Hsp: TLR2
--
e98
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m102
0
infinite
0
--
modofied low density lipoprotein: TLR2
--
e99
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m103
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m119368*m3965*0.1
nodelay
--
0
PMID: 17959357 Anti-viral responses are mediated by TLR4 which senses F protein from RSV, TLR3 which senses double-stranded RNA (poly I:C), TLR7 and TLR8 which sense single-stranded RNA (ss RNA). PMID: 17959357 Moreover, ds-RNA released from necrotic cells and heat shock proteins expressed in the synovial tissue are able to activate TLR-3 and TLR-4, respectively.
p10
p10
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m4645*m3961*0.1
nodelay
--
0
PMID: 17959357 Products of inflamed tissue (e.g. hsp60, fibrinogen products) are sensed by TLR4. PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis. PMID: 17959357 Moreover, ds-RNA released from necrotic cells and heat shock proteins expressed in the synovial tissue are able to activate TLR-3 and TLR-4, respectively.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c265 : 1
stoichiometry:c264 : 1
m24*0.1
nodelay
--
0
PMID: 17959357, 16670522 In the murine model of experimental colitis, TLR-9 signaling may inhibit colonic inflammation via production of type I interferons and the distinctive apical TLR-9 expression and signaling in intestinal epithelial cells is important for the maintenance of colonic homeostasis.
p101
p101
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c266 : 1
stoichiometry:c267 : 1
stoichiometry:c268 : 1
m115*m3965*0.1
nodelay
--
0
PMID: 17959357, 17114417 In this context, TLR-3 stimulation of antigen-presenting cells by the ds-RNA analog poly I:C was able to suppress relapsing demyelination in a murine experimental encephalomyelitis (EAE) model by inducing endogenous IFN-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c270 : 1
stoichiometry:c269 : 1
m116*0.1
nodelay
--
0
PMID: 17959357, 17114417 In this context, TLR-3 stimulation of antigen-presenting cells by the ds-RNA analog poly I:C was able to suppress relapsing demyelination in a murine experimental encephalomyelitis (EAE) model by inducing endogenous IFN-beta.
p103
p103
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c271 : 1
stoichiometry:c272 : 1
stoichiometry:c273 : 1
m19940*m117*0.1
nodelay
--
0
PMID: 17959357, 15611427 Although less thoroughly studied, an important role for TLR signaling has been documented in psoriasis. Local treatment with imiquimod (TLR-7 agonist) resulted in psoriasis exacerbation, which was attributed to the TLR-7 mediated IFN-alpha production by local pDCs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c275 : 1
stoichiometry:c274 : 1
m118*0.1
nodelay
--
0
PMID: 17959357, 15611427 Although less thoroughly studied, an important role for TLR signaling has been documented in psoriasis. Local treatment with imiquimod (TLR-7 agonist) resulted in psoriasis exacerbation, which was attributed to the TLR-7 mediated IFN-alpha production by local pDCs.
p105
p105
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c276 : 1
stoichiometry:c280 : 1
stoichiometry:c278 : 1
m119*m19314*0.1
nodelay
--
0
PMID: 17959357, 15948188 In cultures of human microglia, ligation of TLR3 and TLR4 by double-stranded RNA and LPS, respectively, induces the secretion of the chemokine CXCL10, which is a potent chemoattractant for T cells and is implicated in playing an important role in the MS lesion.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c277 : 1
stoichiometry:c281 : 1
stoichiometry:c279 : 1
m119*m12*0.1
nodelay
--
0
PMID: 17959357, 15948188 In cultures of human microglia, ligation of TLR3 and TLR4 by double-stranded RNA and LPS, respectively, induces the secretion of the chemokine CXCL10, which is a potent chemoattractant for T cells and is implicated in playing an important role in the MS lesion.
p107
p107
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c284 : 1
stoichiometry:c287 : 1
stoichiometry:c286 : 1
m19314*m40*0.1
nodelay
--
0
PMID: 17959357, 16955143 Toll-like receptor 3 mediated activation of macrophages and DCs by LCMV virus, resulting in an increased IFN-alpha and TNF-alpha secretion and thus, self reactive CD8+ cell recruitment has been implicated in the pathogenesis of mouse autoimmune hepatitis.
p108
p108
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c283 : 1
stoichiometry:c285 : 1
stoichiometry:c282 : 1
m93309*m19314*0.1
nodelay
--
0
PMID: 17959357, 16955143 Toll-like receptor 3 mediated activation of macrophages and DCs by LCMV virus, resulting in an increased IFN-alpha and TNF-alpha secretion and thus, self reactive CD8+ cell recruitment has been implicated in the pathogenesis of mouse autoimmune hepatitis.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
m29*m19940*0.1
nodelay
--
0
PMID: 17959357 Anti-viral responses are mediated by TLR4 which senses F protein from RSV, TLR3 which senses double-stranded RNA (poly I:C), TLR7 and TLR8 which sense single-stranded RNA (ss RNA).
p12
p12
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m19823*m29*0.1
nodelay
--
0
PMID: 17959357 Anti-viral responses are mediated by TLR4 which senses F protein from RSV, TLR3 which senses double-stranded RNA (poly I:C), TLR7 and TLR8 which sense single-stranded RNA (ss RNA).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m3961*m33*0.1
nodelay
--
0
PMID: 17959357 Products of inflamed tissue (e.g. hsp60, fibrinogen products) are sensed by TLR4. PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p14
p14
cso30:i:ME_Ubiquitination
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c42 : 1
stoichiometry:c41 : 1
m3962*m36851*0.1
nodelay
--
0
PMID: 17959357, 15928677 Ubiquitination inducing molecules (such as TRIAD 3) that promote TLR degradation; anti-inflammatory molecules (TGF-beta) that directly down-regulate TLR expression; and TLR-induced apoptosis that prevents an excessive inflammatory reaction.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
m35*0.1
nodelay
--
0
PMID: 17959357, 15928677 Ubiquitination inducing molecules (such as TRIAD 3) that promote TLR degradation; anti-inflammatory molecules (TGF-beta) that directly down-regulate TLR expression; and TLR-induced apoptosis that prevents an excessive inflammatory reaction.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c45 : 1
m1746*0.1
nodelay
--
0
PMID: 17959357, 15928677 Ubiquitination inducing molecules (such as TRIAD 3) that promote TLR degradation; anti-inflammatory molecules (TGF-beta) that directly down-regulate TLR expression; and TLR-induced apoptosis that prevents an excessive inflammatory reaction.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m22*m1572*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p18
p18
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
stoichiometry:c52 : 1
stoichiometry:c53 : 1
m17258*m184*m37*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c55 : 1
stoichiometry:c56 : 1
m38*m183*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products: lipopolysaccharide (LPS) is the ligand for TLR4; bacterial lipoproteins (e.g. lipotechoic acid) are recognized by a TLR2/6 dimer; triacylated lipopeptides by a TLR2/1 dimer; CpG oligonucleotides by TLR9; flagellin by TLR5.
p20
p20
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c59 : 1
stoichiometry:c58 : 1
m17*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p21
p21
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c68 : 1
stoichiometry:c61 : 1
m1875*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p22
p22
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c69 : 1
stoichiometry:c63 : 1
m3613*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p23
p23
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c70 : 1
stoichiometry:c65 : 1
m1832*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p24
p24
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c71 : 1
stoichiometry:c67 : 1
m46*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p25
p25
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c72 : 1
stoichiometry:c74 : 1
stoichiometry:c73 : 1
m39*m41*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p26
p26
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c76 : 1
m48*m43*m44*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p27
p27
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c81 : 1
stoichiometry:c82 : 1
stoichiometry:c78 : 1
m63*m45*m1831*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
p28
p28
cso30:i:ME_UnknownActivation
cso30:i:CC_NuclearEnvelopeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c84 : 1
m219*m49*m64*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c88 : 1
m42*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines. PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m13*m15*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products: lipopolysaccharide (LPS) is the ligand for TLR4; bacterial lipoproteins (e.g. lipotechoic acid) are recognized by a TLR2/6 dimer; triacylated lipopeptides by a TLR2/1 dimer; CpG oligonucleotides by TLR9; flagellin by TLR5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c90 : 1
stoichiometry:c91 : 1
m65*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c92 : 1
m66*0.1
nodelay
--
0
PMID: 17959357 MyD88 is the adaptor molecule, used by all but TLR-3 TLRs, which interacts with IRAK4 (IL-1 receptor associated kinase 4) and then with TRAF6 (TNF receptor-associated factor 6), resulting in activation of NF-kappaB and MAP kinases (mitogen-activated protein kinases) and transcription of inflammatory cytokines. PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c96 : 1
stoichiometry:c97 : 1
m1572*m30*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p33
p33
cso30:i:ME_Binding
cso30:i:CC_EndosomeMembrane
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m1572*m31*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c100 : 1
stoichiometry:c101 : 1
m1572*m24*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p35
p35
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c102 : 1
stoichiometry:c108 : 1
stoichiometry:c107 : 1
m184*m68*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p36
p36
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c109 : 1
stoichiometry:c106 : 1
m184*m69*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p37
p37
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c110 : 1
stoichiometry:c105 : 1
m184*m70*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p38
p38
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c113 : 1
stoichiometry:c112 : 1
m183*m71*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c119 : 1
stoichiometry:c116 : 1
m74*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m19*m14*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products: lipopolysaccharide (LPS) is the ligand for TLR4; bacterial lipoproteins (e.g. lipotechoic acid) are recognized by a TLR2/6 dimer; triacylated lipopeptides by a TLR2/1 dimer; CpG oligonucleotides by TLR9; flagellin by TLR5.
p40
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c115 : 1
stoichiometry:c118 : 1
m980*m76*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
p41
p41
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c121 : 1
stoichiometry:c122 : 1
m19314*m18998*0.1
nodelay
--
0
PMID: 17959357 TLR-3 signals through TRIF (Toll/IL-1 receptor domain containing adaptor protein inducing IFN-beta) that activates TBK1 and IRF3 to induce IFN-beta transcription.
p42
p42
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c125 : 1
stoichiometry:c124 : 1
m3902*m19305*0.1
nodelay
--
0
PMID: 17959357 TLR-3 signals through TRIF (Toll/IL-1 receptor domain containing adaptor protein inducing IFN-beta) that activates TBK1 and IRF3 to induce IFN-beta transcription.
p43
p43
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c126 : 1
stoichiometry:c178 : 1
stoichiometry:c127 : 1
m977*m88*0.1
nodelay
--
0
PMID: 17959357 TLR-3 signals through TRIF (Toll/IL-1 receptor domain containing adaptor protein inducing IFN-beta) that activates TBK1 and IRF3 to induce IFN-beta transcription. PMID: 17959357 In the TLR4- and TLR3-mediated signaling pathways, IRF3 is activated via TBK1 and IKKepsilon/IKK-i (MyD88-independent pathway).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c129 : 1
stoichiometry:c130 : 1
m72*m3902*0.1
nodelay
--
0
PMID: 17959357 TRAF6 may also interact with TBK1 (TRAF-family member-associated NF-kappaB activator-binding kinase 2) to activate IRF7 (IFN regulatory factor 7) and result in IFN-alpha induction. This pathway is mediated by TLR-7, TLR-8, TLR-9.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c132 : 1
m75*0.1
nodelay
--
0
PMID: 17959357 TLR-3 signals through TRIF (Toll/IL-1 receptor domain containing adaptor protein inducing IFN-beta) that activates TBK1 and IRF3 to induce IFN-beta transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c134 : 1
m77*0.1
nodelay
--
0
PMID: 17959357 TLR-3 signals through TRIF (Toll/IL-1 receptor domain containing adaptor protein inducing IFN-beta) that activates TBK1 and IRF3 to induce IFN-beta transcription.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c135 : 1
stoichiometry:c136 : 1
stoichiometry:c137 : 1
m3964*m78*0.1
nodelay
--
0
PMID: 17959357 Protozoal glycosyl-phosphatidyl-inositol (GPI-)anchor proteins are recognized by TLR2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c145 : 1
stoichiometry:c139 : 1
m31*0.1
nodelay
--
0
PMID: 17959357 Patients with X-linked agammaglobulinemia exhibit an impaired TLR-8-mediated IL-6 and TNF-alpha production, which may account for their increased susceptibility to enteroviral infections.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c138 : 1
m31*0.1
nodelay
--
0
PMID: 17959357 Patients with X-linked agammaglobulinemia exhibit an impaired TLR-8-mediated IL-6 and TNF-alpha production, which may account for their increased susceptibility to enteroviral infections.
p5
p5
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m3966*m6485*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products: lipopolysaccharide (LPS) is the ligand for TLR4; bacterial lipoproteins (e.g. lipotechoic acid) are recognized by a TLR2/6 dimer; triacylated lipopeptides by a TLR2/1 dimer; CpG oligonucleotides by TLR9; flagellin by TLR5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c143 : 1
stoichiometry:c141 : 1
m93309*0.1
nodelay
--
0
PMID: 17959357 Patients with X-linked agammaglobulinemia exhibit an impaired TLR-8-mediated IL-6 and TNF-alpha production, which may account for their increased susceptibility to enteroviral infections.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c140 : 1
m93248*0.1
nodelay
--
0
PMID: 17959357 Patients with X-linked agammaglobulinemia exhibit an impaired TLR-8-mediated IL-6 and TNF-alpha production, which may account for their increased susceptibility to enteroviral infections.
p52
p52
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c146 : 1
stoichiometry:c147 : 1
stoichiometry:c148 : 1
m12*m6810*0.1
nodelay
--
0
PMID: 17959357 TIR domain-containing adaptor protein (TIRAP)/MyD88-adaptor-like specifically mediates the MyD88-dependent pathway of TLR2 and TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c149 : 1
stoichiometry:c150 : 1
stoichiometry:c151 : 1
m80*m1572*0.1
nodelay
--
0
PMID: 17959357 TIR domain-containing adaptor protein (TIRAP)/MyD88-adaptor-like specifically mediates the MyD88-dependent pathway of TLR2 and TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c153 : 1
stoichiometry:c154 : 1
m6810*m26*0.1
nodelay
--
0
PMID: 17959357 TIR domain-containing adaptor protein (TIRAP)/MyD88-adaptor-like specifically mediates the MyD88-dependent pathway of TLR2 and TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c155 : 1
stoichiometry:c156 : 1
stoichiometry:c157 : 1
m1572*m82*0.1
nodelay
--
0
PMID: 17959357 TIR domain-containing adaptor protein (TIRAP)/MyD88-adaptor-like specifically mediates the MyD88-dependent pathway of TLR2 and TLR4.
p56
p56
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c158 : 1
stoichiometry:c163 : 1
stoichiometry:c166 : 1
m3964*m6220*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p57
p57
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c159 : 1
stoichiometry:c162 : 1
stoichiometry:c165 : 1
m3964*m85*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c217 : 1
stoichiometry:c169 : 1
m102*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c216 : 1
stoichiometry:c168 : 1
m86*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m21*m3962*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c218 : 1
stoichiometry:c167 : 1
m84*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
p61
p61
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c220 : 1
stoichiometry:c173 : 1
m34*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
p62
p62
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c219 : 1
stoichiometry:c174 : 1
m32*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
p63
p63
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c224 : 1
stoichiometry:c175 : 1
m104*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c128 : 1
stoichiometry:c176 : 1
stoichiometry:c177 : 1
m73*m1599*0.1
nodelay
--
0
PMID: 17959357 In the TLR4- and TLR3-mediated signaling pathways, IRF3 is activated via TKB1 and IKKepsilon/IKK-i (MyD88-independent pathway).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c181 : 1
stoichiometry:c179 : 1
m12*m89*0.1
nodelay
--
0
PMID: 17959357 In the TLR4- and TLR3-mediated signaling pathways, IRF3 is activated via TKB1 and IKKepsilon/IKK-i (MyD88-independent pathway).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c182 : 1
stoichiometry:c183 : 1
stoichiometry:c184 : 1
m18998*m90*0.1
nodelay
--
0
PMID: 17959357 In the TLR4- and TLR3-mediated signaling pathways, IRF3 is activated via TKB1 and IKKepsilon/IKK-i (MyD88-independent pathway).
p67
p67
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c185 : 1
stoichiometry:c187 : 1
stoichiometry:c186 : 1
m3902*m91*0.1
nodelay
--
0
PMID: 17959357 In the TLR4- and TLR3-mediated signaling pathways, IRF3 is activated via TBK1 and IKKepsilon/IKK-i (MyD88-independent pathway).
p68
p68
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c188 : 1
stoichiometry:c189 : 1
stoichiometry:c192 : 1
m19940*m92*0.1
nodelay
--
0
PMID: 17959357 Importantly, TLR-3, TLR-7 and TLR-8 recognize endogenous single stranded RNA.
p69
p69
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c190 : 1
stoichiometry:c191 : 1
m19823*m92*0.1
nodelay
--
0
PMID: 17959357 Importantly, TLR-3, TLR-7 and TLR-8 recognize endogenous single stranded RNA.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
m19828*m23*0.1
nodelay
--
0
PMID: 17959357 TLRs are able to recognize a variety of pathogen-derived products: lipopolysaccharide (LPS) is the ligand for TLR4; bacterial lipoproteins (e.g. lipotechoic acid) are recognized by a TLR2/6 dimer; triacylated lipopeptides by a TLR2/1 dimer; CpG oligonucleotides by TLR9; flagellin by TLR5.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c193 : 1
stoichiometry:c194 : 1
stoichiometry:c195 : 1
m19828*m95*0.1
nodelay
--
0
PMID: 17959357, 16492804 Finally, TLR-9 can be stimulated by endogenous hypomethylated DNA; the activation of TLR-9/MyD88 pathway is a prerequisite for switching to pathogenic autoantibody production in a murine model of SLE.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c197 : 1
m96*0.1
nodelay
--
0
PMID: 17959357 The protective effect of TLR-9 may appear at first glance to be paradoxical since it has been well established that the recognition of endogenous nucleic acids by TLR-9 within the endosomal compartment induces B cell proliferation, plasmablast differentiation and, ultimately, production of pathogenic autoantibodies.
PMID: 17959357 The protective effect of TLR-9 may appear at first glance to be paradoxical since it has been well established that the recognition of endogenous nucleic acids by TLR-9 within the endosomal compartment induces B cell proliferation, plasmablast differentiation and, ultimately, production of pathogenic autoantibodies.
PMID: 17959357 The protective effect of TLR-9 may appear at first glance to be paradoxical since it has been well established that the recognition of endogenous nucleic acids by TLR-9 within the endosomal compartment induces B cell proliferation, plasmablast differentiation and, ultimately, production of pathogenic autoantibodies.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c200 : 1
stoichiometry:c201 : 1
1.0*0.1
nodelay
--
0
PMID: 17959357 Hydroxychloroquine, an established treatment for various aspects of lupus and an inhibitor of TLR-9 expression, also inhibited the lupus serum-mediated induction of TLR-9 on plasma cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c205 : 1
stoichiometry:c206 : 1
m100*0.1
nodelay
--
0
PMID: 17959357, 17075805 An enhanced induction of HLA-DR was documented on TLR-9 stimulated (by means of its ligand ODN 2006) B-cells in active but not inactive SLE patients.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c202 : 1
stoichiometry:c203 : 1
stoichiometry:c204 : 1
m19828*m99*0.1
nodelay
--
0
PMID: 17959357, 17075805 An enhanced induction of HLA-DR was documented on TLR-9 stimulated (by means of its ligand ODN 2006) B-cells in active but not inactive SLE patients.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c207 : 1
stoichiometry:c208 : 1
stoichiometry:c209 : 1
m92*m3965*0.1
nodelay
--
0
PMID: 17959357 Importantly, TLR-3, TLR-7 and TLR-8 recognize endogenous single stranded RNA.
p78
p78
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c160 : 1
stoichiometry:c161 : 1
stoichiometry:c164 : 1
m3964*m2254*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p79
p79
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c212 : 1
stoichiometry:c170 : 1
m84*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m13*m25*0.1
nodelay
--
0
PMID: 17959357 A TLR2/6 dimer recognizes zymosan for anti-fungal responses.
p80
p80
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c211 : 1
stoichiometry:c171 : 1
m86*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c210 : 1
stoichiometry:c172 : 1
m102*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
p82
p82
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c213 : 1
stoichiometry:c215 : 1
stoichiometry:c214 : 1
m3964*m2549*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p83
p83
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c221 : 1
stoichiometry:c223 : 1
stoichiometry:c222 : 1
m85*m3961*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p84
p84
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c225 : 1
stoichiometry:c226 : 1
stoichiometry:c227 : 1
m2549*m3961*0.1
nodelay
--
0
PMID: 17959357, 15690042 More specifically, TLR-2 and TLR-4 can be fibrinogen, hyalouronate, heat shock proteins and modified low density lipoprotein, implying a role for their activation in the production of proinflammatory cytokines in the synovial fluid of rheumatoid arthritis patients' or the sterile inflammation of atherosclerosis.
p85
p85
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c228 : 1
stoichiometry:c229 : 1
stoichiometry:c230 : 1
m3962*m2341*0.1
nodelay
--
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c236 : 1
stoichiometry:c233 : 1
m34*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c235 : 1
stoichiometry:c232 : 1
m32*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c234 : 1
stoichiometry:c231 : 1
m106*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
p89
p89
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c238 : 1
stoichiometry:c237 : 1
m106*0.1
nodelay
--
0
PMID: 17959357 The matrix turn-over products generated during the acute tissue injury, provide resident or immune renal cells with abundant endogenous TLR ligands (fibrinogen, hyalouran, fibronectin, HSPs) that may induce the production of reactive oxygen species and of TGF-beta, resulting in collagen production and irreversible renal fibrosis.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m3961*m27*0.1
nodelay
--
0
PMID: 17959357 Anti-viral responses are mediated by TLR4 which senses F protein from RSV, TLR3 which senses double-stranded RNA (poly I:C), TLR7 and TLR8 which sense single-stranded RNA (ss RNA).
p90
p90
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c239 : 1
stoichiometry:c240 : 1
stoichiometry:c241 : 1
m3964*m107*0.1
nodelay
--
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c246 : 1
stoichiometry:c242 : 1
m108*0.1
nodelay
--
0
PMID: 17959357, 12632416 TLR-2 activation of synovial fibroblasts through bacterial peptidoglycans results in upregulation of integrins, matrix metalloproteinases, and inflammatory cytokines (IL-6, IL-8).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c245 : 1
stoichiometry:c243 : 1
m108*0.1
nodelay
--
0
PMID: 17959357, 12632416 TLR-2 activation of synovial fibroblasts through bacterial peptidoglycans results in upregulation of integrins, matrix metalloproteinases, and inflammatory cytokines (IL-6, IL-8).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c247 : 1
stoichiometry:c244 : 1
m108*0.1
nodelay
--
0
PMID: 17959357, 12632416 TLR-2 activation of synovial fibroblasts through bacterial peptidoglycans results in upregulation of integrins, matrix metalloproteinases, and inflammatory cytokines (IL-6, IL-8).
p94
p94
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c248 : 1
stoichiometry:c250 : 1
stoichiometry:c252 : 1
m3961*m111*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
p95
p95
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c249 : 1
stoichiometry:c251 : 1
stoichiometry:c253 : 1
m3964*m111*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
p96
p96
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c254 : 1
stoichiometry:c256 : 1
stoichiometry:c257 : 1
m112*m17*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
p97
p97
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c255 : 1
stoichiometry:c258 : 1
stoichiometry:c259 : 1
m113*m17*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
p98
p98
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c263 : 1
stoichiometry:c260 : 1
m113*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
p99
p99
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c262 : 1
stoichiometry:c261 : 1
m112*0.1
nodelay
--
0
PMID: 17959357, 15814732 Recognition of the urate crystals by TLR-2 and TLR-4 results in release of nitric oxide by chondrocytes, activation of the NF-kappaB transcription factor and thus, expression of several pro-inflammatory cytokines.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--